|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: PCSK2 |
Gene summary for PCSK2 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | PCSK2 | Gene ID | 5126 |
| Gene name | proprotein convertase subtilisin/kexin type 2 | |
| Gene Alias | NEC 2 | |
| Cytomap | 20p12.1 | |
| Gene Type | protein-coding | GO ID | GO:0006508 | UniProtAcc | P16519 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 5126 | PCSK2 | HTA12-15-2 | Human | Pancreas | PDAC | 2.17e-05 | 5.79e-01 | 0.2315 |
| 5126 | PCSK2 | HTA12-23-1 | Human | Pancreas | PDAC | 1.51e-15 | 1.19e+00 | 0.3405 |
| 5126 | PCSK2 | HTA12-25-1 | Human | Pancreas | PDAC | 5.67e-17 | 1.21e+00 | 0.313 |
| 5126 | PCSK2 | HTA12-26-1 | Human | Pancreas | PDAC | 2.74e-44 | 1.51e+00 | 0.3728 |
| 5126 | PCSK2 | HTA12-29-1 | Human | Pancreas | PDAC | 1.85e-87 | 1.61e+00 | 0.3722 |
| 5126 | PCSK2 | HTA12-30-1 | Human | Pancreas | PDAC | 3.25e-02 | 8.60e-01 | 0.3671 |
| 5126 | PCSK2 | HTA12-32-1 | Human | Pancreas | PDAC | 4.48e-04 | 1.23e+00 | 0.3624 |
| 5126 | PCSK2 | HTA12-9-3 | Human | Pancreas | PDAC | 1.52e-08 | 1.09e+00 | 0.2045 |
| 5126 | PCSK2 | PTCwithHT_8 | Human | Thyroid | HT | 1.97e-20 | 8.71e-01 | 0.0351 |
| 5126 | PCSK2 | PTCwithoutHT_2 | Human | Thyroid | PTC | 2.39e-04 | 4.34e-01 | 0.0419 |
| 5126 | PCSK2 | PTCwithoutHT_4_2 | Human | Thyroid | PTC | 9.14e-06 | 8.42e-01 | 0.0455 |
| 5126 | PCSK2 | male-WTA | Human | Thyroid | PTC | 1.46e-26 | 5.24e-01 | 0.1037 |
| 5126 | PCSK2 | female-WTA | Human | Thyroid | PTC | 5.13e-22 | 1.03e+00 | 0.0726 |
| 5126 | PCSK2 | PTC01 | Human | Thyroid | PTC | 6.01e-29 | 1.52e+00 | 0.1899 |
| 5126 | PCSK2 | PTC04 | Human | Thyroid | PTC | 3.30e-76 | 2.34e+00 | 0.1927 |
| 5126 | PCSK2 | PTC05 | Human | Thyroid | PTC | 1.36e-13 | 1.04e+00 | 0.2065 |
| 5126 | PCSK2 | PTC06 | Human | Thyroid | PTC | 7.16e-24 | 2.00e+00 | 0.2057 |
| 5126 | PCSK2 | PTC07 | Human | Thyroid | PTC | 2.11e-46 | 1.56e+00 | 0.2044 |
| Page: 1 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:005160420 | Thyroid | PTC | protein maturation | 132/5968 | 294/18723 | 1.71e-06 | 2.39e-05 | 132 |
| GO:00164859 | Thyroid | PTC | protein processing | 95/5968 | 225/18723 | 6.60e-04 | 4.15e-03 | 95 |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| PCSK2 | SNV | Missense_Mutation | rs769711731 | c.1273N>A | p.Glu425Lys | p.E425K | P16519 | protein_coding | tolerated(0.49) | benign(0.202) | TCGA-AC-A3W5-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | docetaxel | CR |
| PCSK2 | SNV | Missense_Mutation | rs767336020 | c.32N>G | p.Ala11Gly | p.A11G | P16519 | protein_coding | tolerated_low_confidence(0.27) | benign(0) | TCGA-BH-A0HU-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | docetaxel | SD |
| PCSK2 | SNV | Missense_Mutation | c.586N>T | p.Pro196Ser | p.P196S | P16519 | protein_coding | deleterious(0) | probably_damaging(0.983) | TCGA-BH-A0W7-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | taxotere | CR | |
| PCSK2 | SNV | Missense_Mutation | c.1392N>C | p.Glu464Asp | p.E464D | P16519 | protein_coding | tolerated(0.06) | benign(0.091) | TCGA-BH-A208-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| PCSK2 | SNV | Missense_Mutation | c.1484N>C | p.Glu495Ala | p.E495A | P16519 | protein_coding | tolerated(0.86) | benign(0.003) | TCGA-D8-A1XK-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicine+cyclophosphamide | SD | |
| PCSK2 | insertion | Frame_Shift_Ins | novel | c.1423_1424insGTTTTGAATGGTGCATGGAC | p.Asp475GlyfsTer20 | p.D475Gfs*20 | P16519 | protein_coding | TCGA-BH-A0EE-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | docetaxel | SD | ||
| PCSK2 | SNV | Missense_Mutation | novel | c.1276N>A | p.Val426Ile | p.V426I | P16519 | protein_coding | tolerated(0.1) | benign(0.294) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| PCSK2 | SNV | Missense_Mutation | c.1035N>C | p.Glu345Asp | p.E345D | P16519 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-IR-A3LI-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR | |
| PCSK2 | SNV | Missense_Mutation | novel | c.338N>G | p.Asp113Gly | p.D113G | P16519 | protein_coding | tolerated(0.21) | benign(0) | TCGA-VS-A9UZ-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
| PCSK2 | SNV | Missense_Mutation | c.4N>G | p.Lys2Glu | p.K2E | P16519 | protein_coding | tolerated_low_confidence(0.23) | benign(0.027) | TCGA-A6-2677-01 | Colorectum | colon adenocarcinoma | Female | >=65 | III/IV | Ancillary | leucovorin | SD |
| Page: 1 2 3 4 5 6 7 8 9 10 11 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| 5126 | PCSK2 | PROTEASE, ENZYME, DRUGGABLE GENOME | inhibitor | 252166858 |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |